

## *Curriculum Vitae*

Olaf Sommerburg, Privatdozent, Dr. med.

d.o.b. May 30th, 1967, in Sömmerda, Germany

### **University Education**

- 1987 – 1994 Study of Medico Biology and Medicine at the 2<sup>nd</sup> Medical Institute of Moscow, Russia and at the Charité Medical School of the Humboldt-University Berlin, Germany.
- 1995 Doctoral Thesis, Charité Medical School of the Humboldt-University Berlin
- 2005 Habilitation and *venia legendi* in Pediatrics, University of Ulm

### **Medical and Scientific Career**

- 1995 – 1996 Postdoctoral Fellow (DAAD Research Grant) at Dept of Ophthalmology & Visual Sciences, University of Texas Medical Branch at Galveston, TX, USA.
- 1994 – 1995 and 1996 – 2005 Internship and Residency, Department of Pediatrics, University Hospital Charité, Humboldt University Berlin; Department of Pediatrics, University Children's Hospital Heidelberg; Department of Pediatrics, University Children's Hospital Ulm, Germany
- Since 2005 Division of Pulmonology & Allergology, and Cystic Fibrosis Center, University Children's Hospital Heidelberg, Germany.
- 01/2002 Board certified in Pediatrics
- 10/2005 Board certified in Allergology
- 1/2007 Board certified in Pediatric Pulmonology
- 4/2010 Board certified in Infectiology
- Since 2018 Head of Division of Pulmonology & Allergology, and Cystic Fibrosis Center, University Children's Hospital Heidelberg, Germany.

### **Other Professional Activities**

- Since 2008 Board member of the South German Working Group for Allergology and Pediatric Pulmonology (AGPAS)
- Since 2011 Board member of the ECFS Neonatal Screening Working Group
- Since 2012 Board member of the Screening Commission of the German Society of Pediatrics and Adolescent Medicine
- Since 2018 Member of ECFS Diagnostic Network Working Group
- Since 2020 Member of ECFS Clinical Trial Network

### **Honours and Awards**

- 2016 Adolf Windorfer Award, German Cystic Fibrosis Association
- 2019 Meinhard von Pfandler Award, German Foundation „Kindergesundheit“

*Total citations: 5,301; h-index:38; h-index since 2017: 25* (Google Scholar Oct 25<sup>th</sup>, 2022)

## Top-10 selected Publications

Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, **Sommerburg O**#, Dittrich AM#, Tümmler B#, Mall MA#. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med*. 2021 Dec 22. doi: 10.1164/rccm.202110-2249OC. Online ahead of print. (#shared senior authors)

**Olaf Sommerburg**, Mirjam Stahl, Susanne Hämmerling, Gwendolyn Gramer, Martina U. Muckenthaler, Jürgen Okun, Dirk Kohlmüller, Margit Happich, Andreas E. Kulozik, Marcus A. Mall, Georg F. Hoffmann. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net. *J Cyst Fibros*. 2021 Nov 8;S1569-1993(21)02109-3. doi: 10.1016/j.jcf.2021.10.007.

Chung J, Wünnemann F, Salomon J, Boutin S, Frey DL, Albrecht T, Joachim C, Eichinger M, Mall MA, Wielpütz MO, **Sommerburg O**. Increased Inflammatory Markers Detected in Nasal Lavage Correlate with Paranasal Sinus Abnormalities at MRI in Adolescent Patients with Cystic Fibrosis. *Antioxidants (Basel)*. 2021 Sep 3;10(9):1412. doi: 10.3390/antiox10091412.

**Sommerburg O**, Hämmerling S, Schneider SP, Okun J, Langhans CD, Leutz-Schmidt P, Wielpütz MO, Siems W, Gräber SY, Mall MA, Stahl M. CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. *Antioxidants (Basel)*. 2021 Mar 19;10(3):483. doi: 10.3390/antiox10030483.

Gwendolyn G, Brockow I, Labitzke C, Fang-Hoffmann J, Beivers A, Feyh P, Hoffmann GF, Nennstiel U, **Sommerburg O**. Implementing a tracking system for confirmatory diagnostic results after positive newborn screening for cystic fibrosis-implications for process quality and patient care. *Eur J Pediatr*. 2021 Apr;180(4):1145-1155. doi: 10.1007/s00431-020-03849-4.

**Sommerburg O**, Wielpütz MO, Trame JP, Wuennemann F, Optazait E, Stahl M, Puderbach MU, Kopp-Schneider A, Fritzsching E, Kauczor HU, Baumann I, Mall MA, Eichinger M. Magnetic Resonance Imaging Detects Chronic Rhinosinusitis in Infants and Preschool Children with Cystic Fibrosis. *Ann Am Thorac Soc*. 2020 Mar 6. doi: 10.1513/AnnalsATS.201910-777OC.

Stahl, M.; Holfelder, C.; Kneppo, C.; Kieser, M.; Kasperk, C.; Schoenau, E.; **Sommerburg, O.** #; Tönshoff, B. # Increased fracture rate in relation to macroscopic bone architecture in young patients with cystic fibrosis. *J Cyst Fibros*. 2018 Jan;17(1):114-120. doi: 10.1016/j.jcf.2016.06.004. (# shared senior authors)

**Sommerburg, O.**; Hammermann, J.; Lindner, M.; Stahl, M.; Muckenthaler, M.; Kohlmüller, D.; Happich, M.; Kulozik, A. E.; Stopsack, M.; Gahr, M.; Hoffmann, G. F., Mall, M.A. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. *Pediatr Pulmonol*. 2015 Jul;50(7):655-64. doi: 10.1002/ppul.23190. Epub 2015 Apr 23.

**Sommerburg, O.**; Krulisova, V.; Hammermann, J.; Lindner, M.; Stahl, M.; Muckenthaler, M.; Kohlmüller, D.; Happich, M.; Kulozik, A. E.; Votava, F.; Balascakova, M.; Skalicka, V.; Stopsack, M.; Gahr, M.; Macek, M., Jr.; Mall, M. A.; Hoffmann, G. F. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. *J Cyst Fibros*, 13(1): 15-23, 2014

**Sommerburg O**, Lindner M, Muckenthaler M, Kohlmüller D, Leible S, Feneberg R, Kulozik AE, Mall MA, Hoffmann GF. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. *J Inher Metab Dis*. 2010 Oct;33(Suppl 2):S263-71. doi: 10.1007/s10545-010-9174-7.